The utility of integrating nanopore sequencing into routine HIV-1 drug resistance surveillance
Authors:
Open Access
- 20 March 2025
- journal article
- review article
- Published by Microbiology Society in Microbial Genomics
- Vol. 11 (3) , 001375
Abstract
HIV continues to be a significant global public health concern. In 2022, an estimated 29.8 million people living with HIV received antiretroviral treatment (ART). From this, an estimated 10–15% of individuals living with HIV have drug-resistant strains of the virus. Testing for resistance to antiretroviral drugs is recommended before initiating ART. However, such services are often inaccessible due to costs and the need for complex laboratory infrastructure. The assessment of HIV drug resistance (HIVDR) relies on genotyping sequencing and algorithms to interpret genotypic resistance test results. Genotypic assays involve Sanger sequencing of the reverse transcriptase (RT), protease (PR) and integrase (IN) genes of circulating RNA in plasma to detect mutations that are known to confer drug resistance. While state-of-the-art sequencing technologies have swept the globe and enhanced our global pandemic response capabilities, they are still sparingly used for HIVDR surveillance. The scale-up of ART, especially in low- and middle-income countries, necessitates the establishment of cheap, expeditious and decentralized methods for HIVDR monitoring. Here, we outline how one low-capital next-generation sequencing platform, namely, nanopore sequencing, could augment efforts in expanding HIVDR surveillance efforts, especially in resource-limited settings. We discuss that because of its versatility, nanopore sequencing can accelerate HIVDR surveillance in conjunction with scaling up ART efforts and outline some of the challenges that need to be considered before its widespread and routine adaptation to detect drug resistance rapidly.Keywords
Funding Information
- National Institute of Health (R21AI162268)
- Medical Research Council (LID DTP MR/N013638/1)
This publication has 130 references indexed in Scilit:
- Nanopore sequencing technology and its applicationsMedcomm, 2023
- Correction to: Lenacapavir: First ApprovalDrugs, 2023
- Lenacapavir: First ApprovalDrugs, 2022
- A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIVClinical Drug Investigation, 2021
- Integrating and Interpreting Findings from the Latest Treatment as Prevention TrialsCurrent HIV/AIDS Reports, 2020
- What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?Journal of the International AIDS Society, 2020
- Bioinformatic data processing pipelines in support of next‐generation sequencing‐based HIV drug resistance testing: the Winnipeg ConsensusJournal of the International AIDS Society, 2018
- Ibalizumab: First Global ApprovalDrugs, 2018
- Oxford Nanopore MinION Sequencing and Genome AssemblyGenomics, Proteomics & Bioinformatics, 2016
- Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: An open-label, parallel-group studyClinical Therapeutics, 2008